We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

96 hedge funds and large institutions have $107M invested in Palvella Therapeutics in 2020 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 26 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more capital invested

Capital invested by funds: $85.9M → $107M (+$21.2M)

20% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 10

19% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 26

1% more funds holding

Funds holding: 95 → 96 (+1)

0.01% less ownership

Funds ownership: 0.84% → 0.82% (-0.01%)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
96
Holders Change
+1
Holders Change %
+1.05%
% of All Funds
1.97%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
12
Increased
31
Reduced
26
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
CS
Candriam SCA
Luxembourg
+$2.51M
2
WP
Woodline Partners
California
+$1.86M
3
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$1.48M
4
BlackRock
BlackRock
New York
+$621K
5
PIM
Platinum Investment Management
Australia
+$599K

Top Sellers

1
BI
BVF Inc
California
-$8.06M
2
CA
Corriente Advisors
Texas
-$4.42M
3
Morgan Stanley
Morgan Stanley
New York
-$980K
4
EC
EcoR1 Capital
California
-$602K
5
GCP
GSA Capital Partners
United Kingdom
-$414K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
Aquilo Capital Management
California
$17.3M – – –
BlackRock
2
BlackRock
New York
$11.1M +$621K +2,657 +6%
BI
3
BVF Inc
California
$9.66M -$8.06M -34,468 -47%
CS
4
Candriam SCA
Luxembourg
$7.27M +$2.51M +10,716 +58%
Renaissance Technologies
5
Renaissance Technologies
New York
$5.46M -$237K -1,015 -4%
WP
6
Woodline Partners
California
$5.21M +$1.86M +7,954 +61%
SB
7
Samsara BioCapital
California
$5.2M – – –
TCM
8
Tekla Capital Management
Massachusetts
$4.49M – – –
Citadel Advisors
9
Citadel Advisors
Florida
$3.6M -$142K -607 -4%
Vanguard Group
10
Vanguard Group
Pennsylvania
$3.39M +$31.3K +134 +1%
State Street
11
State Street
Massachusetts
$2.86M -$12.2K -52 -0.4%
Acadian Asset Management
12
Acadian Asset Management
Massachusetts
$2.42M +$366K +1,566 +19%
OFM
13
Omega Fund Management
Massachusetts
$2.33M – – –
Geode Capital Management
14
Geode Capital Management
Massachusetts
$2.3M +$72.5K +310 +3%
Northern Trust
15
Northern Trust
Illinois
$1.8M +$101K +433 +6%
PIM
16
Platinum Investment Management
Australia
$1.58M +$599K +2,562 +67%
Assenagon Asset Management
17
Assenagon Asset Management
Luxembourg
$1.57M +$1.48M +6,344 New
PHP
18
Parkman Healthcare Partners
Connecticut
$1.42M -$117K -500 -8%
Citigroup
19
Citigroup
New York
$1.26M -$22.2K -95 -2%
Goldman Sachs
20
Goldman Sachs
New York
$1.1M +$65.7K +281 +7%
LOAMU
21
Lombard Odier Asset Management (USA)
New York
$930K – – –
RPAM
22
Rhenman & Partners Asset Management
Sweden
$930K – – –
Jacobs Levy Equity Management
23
Jacobs Levy Equity Management
New Jersey
$923K -$11K -47 -1%
CA
24
Corriente Advisors
Texas
$837K -$4.42M -18,899 -85%
CHAM
25
Clear Harbor Asset Management
Connecticut
$625K -$45.8K -196 -7%
1
2 3 4 5

PVLA Hedge Fund Activity: Q2 2020 in Review

96 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2020, worth a combined $107M — up 25% from $85.9M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new PVLA positions and 10 closed out — a net gain of 2 holders — while 31 added to existing stakes and 26 trimmed.

The largest buyer was Candriam SCA, adding an estimated $2.51M. The largest seller was BVF Inc, cutting an estimated $8.06M.

  • 96 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2020, up from 95 in Q1 2020.
  • Funds reported $107M of Palvella Therapeutics stock for Q2 2020, up 25% quarter-over-quarter.
  • 12 funds opened new Palvella Therapeutics positions in Q2 2020 and 10 closed out, a net change of +2 holders.
  • The largest Palvella Therapeutics buyer in Q2 2020 was Candriam SCA, an estimated $2.51M added.
  • The largest Palvella Therapeutics seller in Q2 2020 was BVF Inc, an estimated $8.06M sold.

Based on aggregated 13F filings for Q2 2020.